?:abstract
|
-
In the first half of February, WHO announced that the respiratory disease caused by the new coronavirus, is called COVID-19 The most frequent symptoms are fever, asthenia, dry cough;some patients may have variable neurological symptoms, including headache In severe cases, the infection can cause interstitial pneumonia, severe acute respiratory syndrome, kidney failure and even death Due to its epidemiological impact and its spread, the COVID-19 pandemic has had a very significant impact on health care This reflected on the management of acute and chronic neurological patients In the case of headaches, additional problems were added, related to doubts about taking some commonly used drugs on the one hand and the possibility that the new anti-migraine drugs represented by monoclonal antibodies directed against the calcitonin gene related peptide (GCRP) could play a protective role against SARS-CoV-2 infection In this climate of uncertainty, telemedicine has taken on a strategic role in guaranteeing partial continuity of care for cephalalgics © Mattioli 1885
|